BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Lung cancer (all) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for lung cancer: 1323 (417 sponsors; 114 newly posted in the last 180 days, 66 stopped in the last 180 days; 33 new-entrant sponsors). Momentum score 14.4, rank 47 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 8, Phase 1 254, Phase 2 386, Phase 3 222, Phase 4 9, N/A 121.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 85 | P3 29, P4 1, NA 24, P2 25, P1 6 | 5 | 10 |
| Merck Sharp & Dohme LLC MRK | 26 | P3 14, NA 1, P2 11 | 1 | 4 |
| Bristol-Myers Squibb BMY | 25 | P3 9, P2 9, NA 3, P1 4 | 4 | 2 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 24 | P2 9, P3 9, P1 6 | 5 | 7 |
| Amgen AMGN | 18 | P3 7, P1 8, P2 3 | 1 | 3 |
| Daiichi Sankyo | 15 | P2 6, P3 6, P1 2, NA 1 | 2 | 1 |
| Hoffmann-La Roche | 10 | P3 6, NA 2, P2 2 | 0 | 2 |
| Pfizer PFE | 23 | P3 5, P1 8, P2 4, P4 3, NA 3 | 3 | 2 |
| AbbVie ABBV | 13 | P2 3, P3 5, P1 5 | 2 | 0 |
| Akeso | 12 | P3 5, P2 7 | 2 | 2 |
| Qilu Pharmaceutical Co., Ltd. | 7 | P3 5, P2 1, P1 1 | 0 | 3 |
| Eli Lilly and Company LLY | 15 | P1 7, P2 3, P3 4, P4 1 | 1 | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 14 | P3 4, P1 9, P2 1 | 3 | 3 |
| Shanghai Henlius Biotech | 13 | P2 6, P1 3, P3 4 | 1 | 2 |
| GlaxoSmithKline | 8 | P2 3, P3 4, P1 1 | 3 | 0 |
| Shanghai JMT-Bio Inc. | 7 | P2 2, P3 4, P1 1 | 0 | 1 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 12 | P2 9, P3 3 | 3 | 3 |
| Allist Pharmaceuticals, Inc. | 6 | P3 3, P2 3 | 0 | 2 |
| Mirati Therapeutics Inc. | 5 | P2 2, P3 3 | 0 | 0 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 3 | P3 3 | 0 | 1 |
| Janssen Research & Development, LLC | 10 | NA 1, P2 5, P3 2, P1 2 | 0 | 5 |
| Regeneron Pharmaceuticals REGN | 8 | P2 4, P3 2, NA 2 | 0 | 1 |
| Revolution Medicines, Inc. RVMD | 8 | P2 4, P1 2, P3 2 | 1 | 1 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 8 | P2 5, P3 2, P1 1 | 2 | 1 |
| Avistone Biotechnology Co., Ltd. | 7 | P2 4, P3 2, P1 1 | 0 | 0 |
Recently stopped trials
- NCT06980272 Shenyang Sunshine Pharmaceutical Co., LTD. - terminated: Sponsor decided SSGJ-707 in Advanced Non-Small Cell Lung Cancer
- NCT00434226 Genentech, Inc. - terminated: Based on data collected, the combination appeared to be poorly tolearated. A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Ce
- NCT06931626 Nerviano Medical Sciences - terminated: The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but due to a strategic decision drive Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT06107894 NeogenTC - terminated: It is due to difficulties in enrolling participants. TIL Therapy for Patients With Advanced Solid Tumors
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT05132075 Novartis Pharmaceuticals - terminated: Business reasons and not based on any safety concerns. Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-sm
- NCT06756035 Context Therapeutics Inc. - terminated: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termi CT-95 in Advanced Cancers Associated With Mesothelin Expression
- NCT07073183 CureVac - withdrawn: In accordance with 21 CFR 312.38, CureVac is herewith withdrawing IND No. 031346 for CV09070101 (referred to as CVHNLC) for the indication o Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
- NCT07353957 Genmab - withdrawn: This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any saf Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT03371979 Immedica Pharma AB - terminated: Study enrollment was halted early based on ongoing data monitoring; no efficacy analyses were performed Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
- NCT05378763 Spectrum Pharmaceuticals, Inc - suspended: The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA. A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 2
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT06364696 Astellas Pharma Inc - terminated: Company's strategic decision A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P2 | Genentech, Inc. | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | active not recruiting | 99 |
| 2026-11-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | recruiting | 170 |
| 2026-11-30 est. | P2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No | Non-Small Cell Lung Cancer | not yet recruiting | 120 |
| 2026-12 est. | P2 | CivaTech Oncology | NCT03290534 Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® | Lung Cancer; Lung Cancer Stage I; Lung Cancer Stage II | recruiting | 40 |
| 2026-12 est. | P3 | Allist Pharmaceuticals, Inc. | NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small C | Non-small Cell Lung Carcinoma | recruiting | 318 |
| 2026-12 est. | P1/P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Solid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma | recruiting | 170 |
| 2026-12 est. | P1/P2 | AP Biosciences Inc. | NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squam | recruiting | 168 |
| 2026-12 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05482568 A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | recruiting | 324 |
| 2026-12 est. | P1/P2 | Monte Rosa Therapeutics, Inc GLUE | NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients | NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC | active not recruiting | 174 |
| 2026-12 est. | P3 | Mabscale, LLC | NCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | recruiting | 620 |
| 2026-12 est. | P1/P2 | A2 Biotherapeutics Inc. | NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Solid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Small | active not recruiting | 160 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05924841 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer | Small Cell Lung Cancer | recruiting | 100 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05949606 A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 95 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tum | Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma | recruiting | 121 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06114511 A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 78 |
| 2026-12 est. | P2 | Eikon Therapeutics EIKN | NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | NSCLC | active not recruiting | 70 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | Non-small Cell Lung Cancer | active not recruiting | 698 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06437509 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | Extensive-stage Small-cell Lung Cancer | recruiting | 66 |
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | Small Cell Lung Cancer | active not recruiting | 722 |
| 2026-12 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06671379 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | Non-small Cell Lung Cancer | active not recruiting | 498 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | NSCLC | recruiting | 808 |
| 2026-12 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06844474 A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC | NSCLC | recruiting | 300 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12 est. | P1/P2 | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | SCLC, Extensive Stage | recruiting | 27 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12 est. | P3 | Vergent Bioscience, Inc. | NCT07499674 Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | Lung Cancer; Lung Metastases | recruiting | 132 |
| 2026-12-01 est. | P2 | Beijing Biostar Pharmaceuticals Co., Ltd. | NCT06683703 Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | Non-small Cell Lung Cancer Patients with Brain Metastases | not yet recruiting | 118 |
| 2026-12-10 est. | P3 | Boehringer Ingelheim | NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standar | Lung Cancer, Non-squamous, Non-small Cell | active not recruiting | 428 |
| 2026-12-12 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC | NSCLC | not yet recruiting | 680 |
| 2026-12-14 est. | P3 | Amgen AMGN | NCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | active not recruiting | 163 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07145333 Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | SCLC | active not recruiting | 600 |
| 2026-12-25 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06525350 A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed | Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpressio | not yet recruiting | 256 |
| 2026-12-30 est. | P1/P2 | Astellas Pharma Global Development, Inc. | NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metasta | active not recruiting | 240 |
| 2026-12-30 est. | P2 | HC Biopharma Inc. | NCT07169552 HC010 in First-line PD-L1 Positive Advanced NSCLC Patients | NSCLC | recruiting | 50 |
| 2026-12-31 est. | P2 | Partner Therapeutics, Inc. | NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 F | active not recruiting | 250 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2026-12-31 est. | P1/P2 | Avistone Biotechnology Co., Ltd. | NCT06343064 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI | Non-Small-Cell Lung Cancer | recruiting | 156 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2026-12-31 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06961201 Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache | Extensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not | not yet recruiting | 94 |
| 2026-12-31 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer | Resectable Stage II-III Non-small Cell Lung Cancer | not yet recruiting | 10 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01 est. | P1/P2 | iOnctura | NCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC | active not recruiting | 45 |
| 2027-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer | recruiting | 260 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-08 est. | P3 | AstraZeneca AZN | NCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III | Non-Small Cell Lung Cancer | active not recruiting | 1051 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
| 2027-01-18 est. | P2 | AstraZeneca AZN | NCT05374603 Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Lung Cancer | active not recruiting | 47 |
| 2027-01-19 est. | P3 | Hoffmann-La Roche | NCT05170204 A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung C | Non-Small Cell Lung Cancer | active not recruiting | 68 |
| 2027-01-25 est. | P1/P2 | Novartis Pharmaceuticals NVS | NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung | active not recruiting | 344 |
| 2027-01-31 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07202364 A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid | recruiting | 100 |
| 2027-02 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cance | recruiting | 250 |
| 2027-02 est. | P2 | Genelux Corporation GNLX | NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; M | recruiting | 142 |
| 2027-02 est. | P3 | Celltrion | NCT06939595 A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 225 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07467863 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC | Non-Small Cell Lung Cancer; Advanced/Metastatic NSCLC | recruiting | 48 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07480213 Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stage | recruiting | 60 |
| 2027-02-14 est. | P1/P2 | Beijing Biotech | NCT07744256 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-18 est. | P2 | ToLymph Inc. | NCT06693336 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | recruiting | 42 |
| 2026-11-18 est. | P2/P3 | Medicine Invention Design, Inc | NCT05987956 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | 600 |
| 2026-11-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | Small Cell Lung Cancer | active not recruiting | 600 |
| 2026-11 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations | Non-Small-Cell Lung Cancer | recruiting | 40 |
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 406 |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors | recruiting | 200 |
| 2026-11 est. | P1/P2 | Anbogen Therapeutics, Inc. | NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Advanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutations | recruiting | 61 |
| 2026-10-31 est. | P2 | Amgen AMGN | NCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC | active not recruiting | 61 |
| 2026-10-31 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | Non-Small-Cell Lung Cancer | recruiting | 120 |
| 2026-10-30 est. | P1/P2 | Shanghai Henlius Biotech | NCT06848699 A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | Solid Tumor Cancer; Non Small Cell Lung Cancer | recruiting | 105 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-28 est. | P3 | Akeso | NCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | NSCLC (Non-small Cell Lung Cancer) | recruiting | 560 |
| 2026-10-26 | P2 | GlaxoSmithKline | NCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | Lung Cancer, Non-Small Cell | active not recruiting | 351 |
| 2026-10-22 est. | P2 | Shanghai Henlius Biotech | NCT06812260 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC | SCLC, Extensive Stage | active not recruiting | 26 |
| 2026-10-06 | P3 | ArriVent BioPharma, Inc. AVBP | NCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal | Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations | active not recruiting | 398 |
| 2026-10-01 est. | P1/P2 | Inhatarget Therapeutics | NCT06896890 Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | NSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancer | recruiting | 32 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | recruiting | 300 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | 248 |
| 2026-10 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy | Non Small Cell Lung Cancer | recruiting | 522 |
| 2026-09-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors | EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | not yet recruiting | 60 |
| 2026-09-30 est. | P3 | Shanghai JMT-Bio Inc. | NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non | Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previou | recruiting | 516 |
| 2026-09-30 est. | P3 | Beijing Pearl Biotechnology Limited Liability Company | NCT05989542 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) | Non-small Cell Lung Cancer | recruiting | 136 |
| 2026-09-30 est. | P2 | Mirati Therapeutics Inc. | NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Advanced NSCLC; Metastatic Lung Cancer | active not recruiting | 90 |
| 2026-09-30 est. | P1/P2 | J Ints Bio | NCT05394831 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | EGFR Mutant Advanced Non-small Cell Lung Cancer | recruiting | 150 |
| 2026-09-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 506 |
| 2026-09-28 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-S | terminated | 74 |
| 2026-09-22 | P1/P2 | Tango Therapeutics, Inc. TNGX | NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinoma | active not recruiting | 126 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-22 | P3 | Takeda TAK | NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | 354 |
| 2026-09-17 | P2 | Arcus Biosciences, Inc. RCUS | NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 169 |
| 2026-09-15 est. | P1/P2 | Wuhan YZY Biopharma Co., Ltd. | NCT05543330 A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC | Malignant Pleural Effusions; NSCLC Stage IV | recruiting | 116 |
| 2026-09-03 | P3 | Novartis Pharmaceuticals NVS | NCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | terminated | 95 |
| 2026-09-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07169994 A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer | recruiting | 414 |
| 2026-09 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06469879 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients | Small Cell Lung Cancer Limited Stage | unknown | 358 |
| 2026-09 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | Small Cell Lung Cancer; Neuroendocrine Carcinoma | recruiting | 54 |
| 2026-08-31 est. | P2 | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07171606 A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients | First-line Advanced NSCLC Patients | recruiting | 240 |
| 2026-08-31 est. | P3 | mAbxience Research S.L. | NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 726 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-08-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Loca | Non Small Cell Lung Cancer | active not recruiting | 150 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08-20 | P3 | Hansoh BioMedical R&D Company | NCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer | completed | 461 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08-10 | P3 | AstraZeneca AZN | NCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Non-Small Cell Lung Cancer | active not recruiting | 791 |
| 2026-08-01 est. | P1/P2 | OncoResponse, Inc. | NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanom | recruiting | 168 |
| 2026-08-01 est. | P1/P2 | Bridge Biotherapeutics, Inc. | NCT05920135 First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI | EGFR Mutant Advanced Non-Small Cell Lung Cancer | active not recruiting | 24 |
| 2026-08 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervic | not yet recruiting | 120 |
| 2026-08 est. | P3 | Yantai LNC Biotechnology Singapore PTE. LTD. | NCT06416852 Clinical Study of 18F-Alfatide Injection PET/CT | Non-Small Cell Lung Cancer NSCLC | not yet recruiting | 428 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | Non-small Cell Lung Cancer | active not recruiting | 432 |
| 2026-08 est. | P2 | CrystalGenomics, Inc. | NCT05841472 Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non- | Non Squamous Non Small Cell Lung Cancer | recruiting | 60 |
| 2026-08 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Ce | recruiting | 102 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-08 est. | P1/P2 | Allist Pharmaceuticals, Inc. | NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | NSCLC; Solid Tumor | active not recruiting | 315 |
| 2026-07-31 | P3 | Hoffmann-La Roche | NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | completed | 11 |
| 2026-07-30 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01) | EGFR-mutated Locally Advanced or Metastatic NSCLC | recruiting | 380 |
| 2026-07-28 est. | P1/P2 | Lantern Pharma Inc. LTRN | NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Panc | active not recruiting | 64 |
| 2026-07-15 | P1/P2 | EMD Serono Research & Development Institute, Inc. | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | Non-Small Cell Lung Cancer | completed | 61 |
| 2026-07-13 | P1/P2 | GlaxoSmithKline | NCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positro | Lung Cancer, Non-Small Cell | terminated | 2 |
| 2026-07-10 est. | P2 | Shanghai Henlius Biotech | NCT07269782 A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC | Non Small Cell Lung Cancer | recruiting | 60 |
| 2026-07-10 | P3 | AstraZeneca AZN | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tu | Non-small Cell Lung Cancer | active not recruiting | 25 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-07-01 est. | P2/P3 | Shanghai JMT-Bio Inc. | NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer | Squamous Cell Non-small Cell Lung Cancer | not yet recruiting | 534 |
| 2026-07 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung | active not recruiting | 589 |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-07 est. | P2 | Akeso | NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 265 |
| 2026-07 est. | P2 | AbbVie ABBV | NCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | active not recruiting | 270 |
| 2026-06-30 est. | P1/P2 | Suzhou Puhe Pharmaceutical Technology Co., LTD | NCT06590194 PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | 96 |
| 2026-06-30 | P3 | GlaxoSmithKline | NCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) Hig | Lung Cancer, Non-Small Cell | active not recruiting | 88 |
| 2026-06-30 est. | P1/P2 | Akeso | NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 233 |
| 2026-06-30 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05416775 Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | unknown | 168 |
| 2026-06-30 est. | P3 | Shanghai Henlius Biotech | NCT05353257 A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cel | Limited-Stage Small Cell Lung Cancer | active not recruiting | 511 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
| 2026-06-15 | P1/P2 | Verastem, Inc. VSTM | NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant | completed | 12 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-08 | P2 | Dizal Pharmaceuticals | NCT06295432 A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) | Non-small Cell Lung Cancer | completed | 30 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06-01 est. | P2/P3 | Hansoh BioMedical R&D Company | NCT06417008 A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | Non-Squamous Non-Small Cell Lung Cancer | recruiting | 1080 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06496490 A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality | Non-Small Cell Lung Cancer | recruiting | 270 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05913089 A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | recruiting | 58 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P1/P2 | Verastem, Inc. VSTM | NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation | active not recruiting | 153 |
| 2026-06 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT01451853 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy | withdrawn | |
| 2026-05-31 est. | P2 | RemeGen Co., Ltd. | NCT06962865 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or R | Non-Small Cell Lung Cancer | recruiting | 80 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "lung cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.